19 June 2013
Keywords: corcept, initiates, fourth, ph, ii, corlux, study
Article | 31 March 2008
Corcept Therapeutics has announced the commencement of its fourth Phase III trial, Study 14, evaluating Corlux (mifepristone) for the treatment
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
18 June 2013
© 2013 thepharmaletter.com